Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
Neil C Barnes, 1, 2 Dave Singh, 3 David A Lipson 4, 5 1Respiratory Therapy Area, GlaxoSmithKline, Middlesex, UK; 2William Harvey Institute, Bart’s and the London School of Medicine and Dentistry, London, UK; 3Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Rep...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-05-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/reply-to-ldquointraclass-difference-in-pneumonia-risk-with-fluticasone-peer-reviewed-fulltext-article-COPD |